Total Payments
$467,030
2024 Payments
$31,702
Companies
30
Transactions
460
Medicare Patients
673
Medicare Billing
$75,515
Payment Breakdown by Category
Other$341,212 (73.1%)
Consulting$77,388 (16.6%)
Travel$29,371 (6.3%)
Food & Beverage$13,194 (2.8%)
Research$5,820 (1.2%)
Education$46.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $331,402 | 124 | 71.0% |
| Consulting Fee | $77,388 | 40 | 16.6% |
| Travel and Lodging | $29,371 | 95 | 6.3% |
| Food and Beverage | $13,194 | 191 | 2.8% |
| Honoraria | $9,810 | 5 | 2.1% |
| Unspecified | $5,820 | 1 | 1.2% |
| Education | $46.03 | 4 | 0.0% |
Payments by Type
General
$461,210
459 transactions
Research
$5,820
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $143,508 | 112 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $126,457 | 106 | $0 (2024) |
| Genentech USA, Inc. | $57,809 | 50 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $46,928 | 58 | $0 (2019) |
| Advanced Accelerator Applications | $30,853 | 25 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $18,498 | 22 | $0 (2024) |
| Curium US LLC | $13,845 | 24 | $0 (2021) |
| Exelixis Inc. | $13,359 | 20 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $3,371 | 4 | $0 (2023) |
| LANTHEUS MEDICAL IMAGING, INC. | $2,875 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,702 | 39 | Exelixis Inc. ($13,359) |
| 2023 | $32,855 | 21 | AstraZeneca Pharmaceuticals LP ($29,514) |
| 2022 | $52,977 | 44 | AstraZeneca Pharmaceuticals LP ($34,883) |
| 2021 | $68,275 | 48 | Ipsen Biopharmaceuticals, Inc ($51,208) |
| 2020 | $63,225 | 46 | Ipsen Biopharmaceuticals, Inc ($35,969) |
| 2019 | $71,488 | 81 | Genentech USA, Inc. ($14,115) |
| 2018 | $68,887 | 70 | Genentech USA, Inc. ($25,344) |
| 2017 | $77,622 | 111 | Merck Sharp & Dohme Corporation ($20,454) |
All Payment Transactions
460 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $1,808.49 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $443.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $122.69 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $97.50 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $57.92 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $17.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $62.92 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $58.60 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $132.43 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/08/2024 | Galderma Laboratories, L.P. | DYSPORT | Food and Beverage | In-kind items and services | $195.75 | General |
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $117.99 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $49.00 | General |
| Category: Oncology | ||||||
| 07/09/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,835.00 | General |
| 06/26/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Consulting Fee | Cash or cash equivalent | $3,525.00 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Consulting Fee | Cash or cash equivalent | $36.05 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Consulting Fee | Cash or cash equivalent | $22.78 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug), LUTATHERA | Food and Beverage | In-kind items and services | $3.96 | General |
| Category: Oncology | ||||||
| 06/18/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Food and Beverage | In-kind items and services | $40.24 | General |
| 06/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/24/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,820 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 251 | 393 | $142,422 | $29,034 |
| 2022 | 3 | 85 | 158 | $51,019 | $11,635 |
| 2021 | 3 | 95 | 120 | $43,012 | $10,494 |
| 2020 | 6 | 242 | 359 | $88,249 | $24,352 |
Total Patients
673
Total Services
1,030
Medicare Billing
$75,515
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 87 | 141 | $44,838 | $8,670 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 99 | $31,482 | $6,957 | 22.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 58 | $17,574 | $3,414 | 19.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $16,068 | $3,060 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $14,214 | $2,810 | 19.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 21 | $9,009 | $2,021 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 13 | $5,577 | $1,383 | 24.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $3,660 | $718.68 | 19.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 40 | 80 | $25,440 | $5,661 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 38 | $12,084 | $2,677 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $9,270 | $1,963 | 21.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 25 | $4,225 | $1,333 | 31.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 43 | 56 | $15,235 | $3,897 | 25.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 25 | $7,120 | $1,798 | 25.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $8,163 | $1,750 | 21.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $7,253 | $1,694 | 23.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 13 | $5,241 | $1,355 | 25.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 94 | 169 | $40,435 | $10,371 | 25.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 63 | $14,805 | $4,002 | 27.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 28 | 38 | $12,046 | $3,526 | 29.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 20 | 20 | $9,100 | $2,481 | 27.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 12 | 15 | $4,755 | $1,366 | 28.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 25 | $4,000 | $1,053 | 26.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 13 | 15 | $1,890 | $964.05 | 51.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 13 | 14 | $1,218 | $588.84 | 48.3% |
About Dr. Robert Ramirez, D.O
Dr. Robert Ramirez, D.O is a Internal Medicine healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1669665808.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Ramirez, D.O has received a total of $467,030 in payments from pharmaceutical and medical device companies, with $31,702 received in 2024. These payments were reported across 460 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($331,402).
As a Medicare-enrolled provider, Ramirez has provided services to 673 Medicare beneficiaries, totaling 1,030 services with total Medicare billing of $75,515. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Nashville, TN
- Active Since 08/21/2007
- Last Updated 11/07/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669665808
Products in Payments
- SOMATULINE DEPOT (Drug) $110,753
- TAGRISSO (Drug) $73,138
- KEYTRUDA (Biological) $46,821
- LUTATHERA (Drug) $36,334
- TECENTRIQ (Biological) $34,192
- IMFINZI (Biological) $32,000
- IMFINZI (Drug) $21,315
- Somatuline Depot 120mg-.5ml (Drug) $17,262
- Somatuline Depot (Drug) $14,319
- CABOMETYX (Drug) $13,359
- Avastin (Biological) $9,808
- Detectnet (Drug) $8,875
- Alecensa (Biological) $8,218
- SANDOSTATIN LAR (Drug) $5,339
- ROZLYTREK (Biological) $4,940
- Cu64 Dotatate (Drug) $4,921
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $4,128
- LIBTAYO (Biological) $3,371
- AFINITOR (Drug) $2,777
- Tepmetko (Drug) $2,100
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Nashville
Mr. John Anderson, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Sandeep Rajan, M.d, M.D
Internal Medicine — Payments: $709,151
Internal Medicine $709,151
Dr. Christopher Ellis, M.d, M.D
Internal Medicine — Payments: $618,290
Internal Medicine $618,290
Dr. Brian Jefferson, Md, MD
Internal Medicine — Payments: $514,499
Internal Medicine $514,499
Dr. Michael Morse, M.d, M.D
Internal Medicine — Payments: $444,237
Internal Medicine $444,237
Kashish Goel
Internal Medicine — Payments: $407,393
Internal Medicine $407,393